Description

Nifedipine Tablet

Nifedipine Modified & Extended-Release Tablets (10 mg / 20 mg / 30 mg / 60 mg)

Healthy Life Pharma Private Limited, alongside our global marketing and export division Healthy Inc, is a premier Indian manufacturer, CDMO partner, and wholesale exporter of advanced cardiovascular, anti-hypertensive, and maternal-fetal therapeutics. We manufacture a comprehensive, internationally standardized range of Nifedipine Tablets (10 mg / 20 mg / 30 mg / 60 mg) within our WHO–GMP certified, high-precision solid dosage manufacturing installations. This foundational “Dihydropyridine Calcium Channel Blocker” serves as a high-volume strategic export to cardiology centers, institutional state hospital networks, public health ministry tenders, and international B2B wholesale marketplaces across Africa, the CIS region, LATAM, and Southeast Asia.

Product Overview

This formulation operates as a “Selective Smooth Muscle Calcium Channel Antagonist.” It ensures patient safety by chemically blocking calcium influx into vascular tissue, physically relaxing peripheral and coronary arterial walls to reduce systemic blood pressure and prevent ischemic chest pain.

• Mechanism 1 (L-Type Calcium Channel Inhibition): Nifedipine physically binds to and chemically blocks L-type voltage-gated calcium channels within vascular smooth muscle cells. This halts the intracellular calcium influx necessary for muscle contraction.

• Mechanism 2 (Profound Systemic Vasodilation): By preventing contraction, it chemically reduces total peripheral vascular resistance (afterload). This physically lowers systemic blood pressure and reduces the mechanical workload of the heart.

• Mechanism 3 (Coronary Perfusion Enhancement): It physically dilates both normal and ischemic coronary arteries, preventing spontaneous coronary spasms and chemically maximizing oxygen delivery to the myocardium.

Product Composition & Structural Formats

We manufacture Nifedipine across the complete clinical dosage spectrum, utilizing distinct release matrices calibrated for immediate stabilization or sustained, once-daily therapeutic coverage.

Technical & Logistics Specifications

• HS Code: 3004.90.99 (Medicaments acting on the cardiovascular system / Calcium channel blockers)

• CAS Number: 21829-25-4 (Nifedipine)

• Dosage Formats: Oral Solid Film-Coated Tablets, Sustained-Release, or Once-Daily Extended-Release Tablets.

• Packaging Configurations: 10 / 14 / 15 Tablets per Blister packed exclusively in high-barrier Alu-Alu (Cold-Form Foil) or light-resistant amber PVC/PVDC matrix strips.

Photo-Shielding Engineering & Extended-Release Kinetics

• Advanced Light-Deactivation Prevention: Nifedipine crystals are highly physically unstable when exposed to daylight, rapidly breaking down into inactive chemical byproducts. We maintain an Isolated, UV-Filtered Light Environment across our entire blending, granulating, and tableting lines, ensuring complete molecular integrity prior to opaque foil packaging.

• 24-Hour Hydrophilic Polymer Matrix: For our high-potency 30 mg and 60 mg extended-release variants, we utilize an Advanced Hydrophilic HPMC Matrix Network. This system controls the physical rate of gastrointestinal fluid entry, chemically releasing the drug uniformly over 24 hours. This eliminates the dangerous “peak-and-trough” plasma fluctuations that trigger reflex tachycardia.

• Bioequivalence Verification: Every export batch physically undergoes Automated Dissolution Profiling, chemically validating that our generic formulations precisely replicate the kinetic performance curves of global innovator standards (such as Adalat XL / Procardia XL).

Primary Indications

• Cardiology: Long-term management and prophylaxis of Chronic Stable Angina Pectoris and Vasospastic (Prinzmetal’s) Angina.

• Internal Medicine: Comprehensive management of mild, moderate, and severe Essential Hypertension.

• Obstetrics & Gynecology: Off-label deployment as a frontline Tocolytic Agent to delay premature labor and suppress acute pre-eclamptic hypertensive crises.

Usage Instructions

• The Crushing Mandate: Extended-release (20 mg / 30 mg / 60 mg) tablets must be swallowed physically whole with a glass of water. Never crush, chew, or split the tablet. Damaging the tablet core chemically destroys the polymer matrix, physically releasing the entire dose immediately (dose-dumping), which can lead to life-threatening hypotension.

• The Grapefruit Restriction: Patients must completely avoid consuming grapefruit juice with Nifedipine. Grapefruit chemically inhibits the intestinal CYP3A4 metabolic enzyme, physically multiplying drug plasma concentrations to toxic levels.

• Gradual Discontinuation: Doses must never be halted abruptly. Sudden withdrawal can chemically destabilize vascular tone, physically triggering severe rebound hypertension or acute coronary spasms.

Safety Warning: POTENT CARDIOVASCULAR MODIFIER. For Professional Medical Supervision Only. Reflex Tachycardia Risk: Immediate-release forms may cause rapid peripheral vasodilation followed by sympathetic Reflex Tachycardia; manage acute titration windows carefully. Peripheral Edema Note: Vasodilation can physically cause localized fluid shifts in the lower extremities (ankle swelling); evaluate parameters chemically if fluid retention persists. Contraindication: Do not use in cases of cardiogenic shock, severe aortic stenosis, within 4 weeks of a myocardial infarction, or known hypersensitivity to dihydropyridine derivatives.

Global CDMO Services & Wholesale Supply Chain

Healthy Life Pharma Private Limited and Healthy Inc provide complete, internationally validated Third-Party Contract Manufacturing (CDMO Services) and high-volume private-label production for the entire Nifedipine dosage spectrum. Whether you are fulfilling a high-volume procurement contract for a National Health Ministry Tender, stocking state hospital infrastructure in the CIS, or injecting inventory into a digital B2B Pharmaceutical Marketplace across Southeast Asia or LATAM, we deliver all required documentation (WHO-GMP Certificate, COPP, COA, Stability Testing Matrix Sheets, and Complete CTD Format Dossier sets) for rapid entry registration.

Commercial & Bulk Procurement Inquiries:

• Corporate Head Office: Mumbai, Maharashtra, India

• Primary Manufacturing Base: Boisar, Maharashtra, India

• WhatsApp / Direct Call: +91 7710003340

• Corporate Email: info@healthyinc.co.in